Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 Window of Opportunity in Recurrent SCCHN
NCT04588038Phase 1Terminated
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in head and neck squamous cell carcinoma (HNSCC). Primary endpoints: Proportion of treatment-related adverse events at 35 days and Number of participants who completed course of NT-I7 at 43 days. Started Mar 2021; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04588038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588038.